We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunochromatography Quantifies Prostate Specific Antigen

By LabMedica International staff writers
Posted on 18 Jan 2012
A fluorescence immunochromatography method using monoclonal antibodies to prostate specific antigen (PSA) has been developed.

The fluorescence immunochromatographic analysis system is composed of anti-PSA-monoclonal antibody (mAb), fluorescence conjugates in a detection solution, a immunochromatographic assay strip, and a laser fluorescence scanner. More...


Scientists at Kangwon National University (Chuncheon, Korea) have developed a fluorescence immunochromatographic assay strip consists of a nitrocellulose membrane, a sample pad, an absorption pad, and a backing card. The fluorescence immunochromatographic-analysis system was employed to detect PSA based on the area ratio between the control line and the test line of the strip. The test line on the nitrocellulose membrane was dispensed with anti-PSA-mAb; the detection solution was a mixture of anti-PSA-mAb- fluorescent (FL) conjugate and biotin-bovine serum albumin (BSA)-FL conjugate.

Serum obtained from a healthy man, was spiked with PSA to produce five different concentrations: 0.72 ng/mL, 2.3 ng/mL, 4.6 ng/mL, 11.5 ng/mL, 23 ng/mL. These five human sera samples when applied on to the fluorescence immunochromatographic strip which detected PSA concentrations in the human sera samples correlating consistently with the assumed vales. The optimum incubation time of test samples would be exactly 20 minutes, since the standard curve data stored in the fluorescence scanner would be obtained with an incubation time of 20 minutes.

Prostate-specific monoclonal antibody (anti-PSA-mAb) was supplied by Boditech. (Chuncheon, Korea), and prostate-specific antigen (PSA) was obtained from Sigma Aldrich (St. Louis, MO, USA). Under optimal conditions, the area ratio was proportional to PSA concentration ranged from the lowest detection limit of 0.72 ng/mL to 46.0 ng/mL. The authors concluded that as the fluorescence immunochromatography assay is easy to perform and its quantitative range is within PSA concentrations in human blood samples, it shows a potential to be a powerful tool in quantitative analysis of PSA in human blood samples. The study was published in October 2010 in the Journal of Immunoassay and Immunochemistry.

Related Links:
Kangwon National University
Boditech
Sigma Aldrich


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.